On June 27, 2019, the U.S. Food and Drug Administration (FDA) approved daratumumab (Darzalex®) in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.
Approval was based on MAIA (NCT02252172), an open-label, randomized (1:1), active-controlled phase III study, comparing dartumumab (16 mg/kg) in combination with lenalidomide and low-dose dexamethasone (DRd) to lenalidomide and low-dose dexamethasone (Rd), in 737 patients with newly diagnosed multiple myeloma who were ineligible for autologous stem cell transplant.
The trial demonstrated an improvement in progression-free survival (PFS) in the DRd arm compared with the Rd arm. The median PFS had not been reached in the DRd arm and was 31.9 months in the Rd arm (hazard ratio = 0.56; 95% CI = 0.43, 0.73; p < 0.0001). The median time to response was 1.05 months (range = 0.2–12.1 months) in the DRd group and 1.05 months (range = 0.3–15.3 months) in the Rd group. The median response duration had not been reached in the DRd group and was 34.7 months (95% CI = 30.8, not estimable) in the Rd group.
Daratumumab can cause severe or serious infusion reactions, including anaphylactic reactions. Approximately half of all patients in clinical trials experienced an infusion reaction. Patients should be premedicated with antihistamines, antipyretics, and corticosteroids. Frequently monitoring patients during the entire infusion is recommended.
In newly diagnosed patients with multiple myeloma who received daratumumab in combination with lenalidomide and dexamethasone, the most frequent (≥ 20%) adverse reactions were infusion reactions, diarrhea, constipation, nausea, peripheral edema, fatigue, back pain, asthenia, pyrexia, upper respiratory tract infection, bronchitis, pneumonia, decreased appetite, muscle spasms, peripheral sensory neuropathy, dyspnea, and cough.
The recommended daratumumab dose is 16 mg/kg actual body weight. View full prescribing information for drugs used in combination and schedule.
This application used the Real-Time Oncology Review. FDA granted this application priority review. A description of FDA expedited programs is in the Guidance for Industry: Expedited Programs for Serious Conditions—Drugs and Biologics.
Healthcare professionals should report all serious adverse events suspected to be associated with the use of any medicine and device to FDA’s MedWatch Reporting System or by calling 800-FDA-1088.
In collaboration with the FDA and as a service to our members, ONS provides updates on recent FDA approvals and other important FDA actions (e.g., updated safety information, new prescribing information) pertaining to therapies for patients with cancer. This allows the agency to inform oncologists and professionals in oncology-related fields in a timely manner. Included in the FDA updates is a link to the product label or to other sites for additional relevant clinical information. In supplying this information, ONS does not endorse any product or therapy and does not take any position on the safety or efficacy of the product or therapy described.